Vernalis PLC

Vernalis PLC is a UK-based biopharmaceutical company specializing in drug discovery and development services, focusing on innovative solutions for complex therapeutic targets. Vernalis PLC, founded in 1988 in the UK, engages in drug discovery services. The company underwent a significant change in ownership when Ligand Pharmaceuticals, Inc. acquired Vernalis for GBP 32.

80 million on August 9, 2018. The founder, Ana Cimbleris, has a background in biopharmaceutical ventures. The company has completed a total of three deals to date. Vernalis (R&D) Limited specializes in drug discovery services, applying over 25 years of experience in structure-based methodologies to tackle complex therapeutic targets.

Their core offerings include protein production and engineering, hit compound identification and validation, and the development of chemical series into pre-clinical candidates. Vernalis employs techniques like fragment-based methods, DNA Encoded Library (DEL) technology, and medium-throughput biochemical screening. Their clientele features a diverse array of pharmaceutical and biotechnology companies, including partnerships with Servier, Pierre Fabre, and Genentech, primarily serving markets in Europe and North America. In the most recent year of 2024, Vernalis reported a revenue of GBP 16,373,955.

60 and an EBITDA of GBP 2,971,621. 80. The company generates revenue through collaborative partnerships and research agreements in the biopharmaceutical sector, focusing on long-term and project-based transactions with clients in B2B relationships. Vernalis is focused on expanding its portfolio of drug discovery services while targeting new markets, particularly in North America and Europe.

The recent funding of GBP 32. 80 million will support these initiatives, allowing for the development of new products and the enhancement of existing capabilities. The investment from Ligand Pharmaceuticals, Inc. is expected to facilitate the acceleration of product launches and expand operational capacity to meet growing demand in the biopharmaceutical landscape.